William Blair Predicts Increased Earnings for Genmab A/S

Genmab A/S (NASDAQ:GMAB) – Research analysts at William Blair raised their FY2024 earnings per share (EPS) estimates for shares of Genmab A/S in a note issued to investors on Wednesday, November 6th. William Blair analyst M. Phipps now expects that the company will earn $1.24 per share for the year, up from their previous forecast of $1.22. The consensus estimate for Genmab A/S’s current full-year earnings is $1.29 per share. William Blair also issued estimates for Genmab A/S’s Q4 2024 earnings at $0.34 EPS, FY2025 earnings at $1.60 EPS, FY2026 earnings at $2.52 EPS and FY2027 earnings at $3.56 EPS.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a net margin of 23.49% and a return on equity of 14.73%. The business had revenue of $779.50 million during the quarter, compared to the consensus estimate of $734.60 million.

A number of other research analysts have also commented on GMAB. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a report on Friday. Royal Bank of Canada raised Genmab A/S from a “sector perform” rating to an “outperform” rating in a report on Monday, July 15th. Redburn Atlantic assumed coverage on Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Wednesday, October 16th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Genmab A/S currently has an average rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $23.08 on Friday. The company has a market cap of $15.27 billion, a PE ratio of 22.41, a price-to-earnings-growth ratio of 0.66 and a beta of 0.99. The firm has a fifty day moving average price of $24.39 and a two-hundred day moving average price of $26.41. Genmab A/S has a fifty-two week low of $21.90 and a fifty-two week high of $32.89.

Institutional Trading of Genmab A/S

Several institutional investors have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC bought a new position in shares of Genmab A/S during the first quarter valued at $43,000. Janney Montgomery Scott LLC lifted its holdings in Genmab A/S by 43.2% during the 1st quarter. Janney Montgomery Scott LLC now owns 17,369 shares of the company’s stock valued at $520,000 after purchasing an additional 5,238 shares during the last quarter. Envestnet Portfolio Solutions Inc. boosted its position in Genmab A/S by 2.3% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 27,755 shares of the company’s stock valued at $830,000 after buying an additional 633 shares in the last quarter. SG Americas Securities LLC grew its stake in Genmab A/S by 360.5% during the first quarter. SG Americas Securities LLC now owns 29,500 shares of the company’s stock worth $882,000 after buying an additional 23,094 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of Genmab A/S by 137.7% during the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after buying an additional 544 shares in the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.